Chronic heart failure: Developments and perspectives

Consultant Pharmacist

Volumn 20, Issue 9, 2005, Pages 751-765

  Crouch, Michael A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

ACE inhibitor; Aldosterone antagonist; Angiotensin II receptor blocker; Beta adrenergic blocker; Chronic heart failure; Diastolic dysfunction; Digoxin; Diuretic; Systolic dysfunction

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE ANTAGONIST; AMIODARONE; ANDROGEN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DIURETIC AGENT; DOFETILIDE; DOXORUBICIN; ESTROGEN; FLECAINIDE; GLUCOCORTICOID; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; ITRACONAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; ROSIGLITAZONE; SALICYLIC ACID DERIVATIVE; TERBINAFINE; TICARCILLIN; UNINDEXED DRUG; VERAPAMIL;

ARTIFICIAL HEART PACEMAKER; BLOOD PRESSURE REGULATION; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL PROTOCOL; DEFIBRILLATOR; DIASTOLE; DISEASE CLASSIFICATION; EVIDENCE BASED PRACTICE; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERVOLEMIA; MEDICAL SOCIETY; MEDLINE; PATHOPHYSIOLOGY; PHARMACIST; PRACTICE GUIDELINE; REVIEW; SURVIVAL; SYSTOLE; TACHYCARDIA;

EID: 33748028849     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2005.751     Document Type: Review

References (46)

1. Colucci WS, Braunwald E. Pathophysiology of heart failure. In: Braunwald E, Zipes DP, Libby P, editors. Heart disease: a textbook of cardiovascular medicine. 6th ed. Philadelphia, PA: Saunders; 2001:503-33.
2. Francis GS, Tang WH. Pathophysiology of congestive heart failure. Rev Cardiovasc Med 2003;4(suppl 2):s14-s20.
3. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. Dallas, Tex: American Heart Association; 2005.
4. HFSA guidelines for management of patients with heart failure caused by left-ventricular systolic dysfunction - pharmacological approaches. Heart Failure Society of America. Pharmacotherapy 2000;20:1-36.
5. Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. J Am Coll Cardiol 2001;38:2101-13.
6. The Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2005;26:1115-40.
7. O'Connell JB. The economic burden of heart failure. Clin Cardiol 2000;23:(supp 3)1116-1110.
8. Ranz TT, Blumenschein K, Clifton GD. Prevalence and treatment of heart failure in elderly long-term care patients. Am J Health Syst Pharm 1999;56:1334-8.
9. Hambassi G, Forman DE, Capone KL et al. Management of heart failure among very old persons living in longer term care: Has the voice of trials spread? The SAGE Study Group. Am Heart J 2000;139:85-93.
10. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997;133:703-12.
11. Haldeman GA, Croft JB, Giles WH et al. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 1999;137:352-60.
12. Sharpe N, Doughty R. Epidemiology of heart failure and ventricular dysfunction. Lancet 1998;352 (suppl 1):s13-s17.
13. Aurigemma GP, Gaasch WH. Diastolic heart failure. N Engl J Med 2004;351:1097-105.
14. Davie AP, Francis CM, Caruana L et al. The prevalence of left ventricular diastolic filling abnormalities in patients with suspected heart failure. Eur Heart] 1997;18:981-4.
15. The Criteria Committee of the New York Heart Association. Diseases of the Heart and Bloodvessels: Nomenclature and Criteria for Diagnosis. 6th ed. Boston, MA: Little Brown, 1964.
16. American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, TX.: American Heart Association; 2001.
17. Crouch MA. Contemporary management of heart failure. Consult Pharm 2002;17 (suppl 1):s1-s14.
18. Braith RW. Exercise training in patients with CHF and heart transplant recipients. Med Sci Sports Exerc 1998;30:s367-s378.
19. Vinson JM, Rich MW, Sperry JC et al. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc 1990;38:1290-5.
20. Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomized controlled trial. Lancet 2003;362:7-13.
21. Gattis WA, O'Conner CM, Gallup DS et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. J Am Coll Cardiol 2004;43:1534-41.
22. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
23. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
24. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351:543-51.
25. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
26. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
27. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
28. Granger CB, McMurry, JJV, Yusuf S et al. Effects of candasartan in patients with chronic heart failure and educed left-ventricular systolic dysfunction intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 2003;362:772-6.
29. McMurray JJV, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
30. Uretsky BF, Young JB, Shahidi FE et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993;22:955-62.
31. Packer M, Gheorghiade M, Young JB et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. N Engl J Med 1993;329:1-7.
32. The digitalis investigation group. The effects of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
33. Rathore SS, Wang Y, Krumholtz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347:1403-11.
34. Rathore SS, Curtis IP, Wang Y et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871-8.
35. Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of the Veterans Administration Cooperative Study. N Engl J Med 1986;316:1547-52.
36. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
37. Carson P, Ziesche S, Johnson G et al. Racial differences in response to therapy for heart failure: analysis of the vasodilator heart failure trials. J Card Fail 1999;5:178-87.
38. Exner DV, Dries DL, Domanski MJ et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-7.
39. Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-57.
40. Cleland JGF, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352.
41. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM Preserved Trial. Lancet 2003;362:777-81.
42. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52.
43. Gattis WA, Hasselbald V, Whellan DJ et al. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med 1999;159:1939-45.
44. Jain A, Mills P, Nunn LM et al. Success of a multidisciplinary heart failure clinic for initiation and up-titration of key therapeutic agents. Eur J Heart Fail 2005;7:405-10.
45. Tsuyuki RT, Fradette M, Johnson JA et al. A multicenter disease management program for hospitalized patient with heart failure. J Card Fail 2004;10:473-80.
46. Holland R, Battersby J, Harvey I et al. Systematic review of multidisciplinary interventions in heart failure. Heart 2005;91:899-906.